Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, M-210 Starling Loving Hall, 320 W. 10th Avenue, Columbus, OH, 43210, USA.
Curr Treat Options Oncol. 2024 Jul;25(7):854-868. doi: 10.1007/s11864-024-01205-4. Epub 2024 Jun 13.
Low grade serous carcinoma of the ovary has been delineated as a separate entity from its counterpart high grade serous carcinoma of the ovary. Molecular profiling has helped to further characterize this disease process and has led to new and exciting treatment options. Surgery has always been a cornerstone of management both in primary and recurrent disease settings. Chemotherapy has been a long-standing backbone of adjuvant treatment, but its efficacy continues to be questioned. Hormonal therapy for upfront and recurrent disease is an effective treatment option with a high response rate and minimal side effects. Newer therapies including MEK, CDK 4/6, and PI3KCA inhibitors have emerged as exciting options for recurrent disease. Ongoing clinical trials will hopefully lead to additional therapeutic opportunities based on novel biomarkers in this disease.
卵巢低级别浆液性癌已被明确为一种独立的实体，与卵巢高级别浆液性癌相对。分子谱分析有助于进一步描述这一疾病过程，并带来了新的令人兴奋的治疗选择。手术一直是原发性和复发性疾病管理的基石。化疗一直是辅助治疗的重要支柱，但它的疗效仍受到质疑。激素治疗是一种有效的治疗方法，用于初治和复发性疾病，具有高反应率和最小的副作用。新型治疗方法，包括 MEK、CDK4/6 和 PI3KCA 抑制剂，已成为复发性疾病的令人兴奋的选择。正在进行的临床试验有望基于该疾病的新型生物标志物为患者带来更多的治疗机会。
